Abeona Therapeutics (Abeona Therapeutics) Cash per Share : $2.26 (As of Mar. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Abeona Therapeutics's Cash per Share for the quarter that ended in Mar. 2024 was $2.26.

Abeona Therapeutics Cash per Share Historical Data

The historical data trend for Abeona Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Cash per Share Chart

Abeona Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

38.64

24.72

7.65

2.94

1.97

Abeona Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash per Share	Get a 7-Day Free Trial															2.25	1.71	2.18	1.97	2.26

Abeona Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Abeona Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	52.226	/	26.52
	=	1.97

Abeona Therapeutics's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	62.344	/	27.55
	=	2.26

Abeona Therapeutics (NAS:ABEO) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Abeona Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Abeona Therapeutics (Abeona Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (NAS:ABEO) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

PCJ:Germany PCJ:Germany

Address

1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019

Website

https://www.abeonatherapeutics.com

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.

Executives

Mark Alvino	director	C/O SCO SECURITIES LLC, 1285 AVENUE OF THE AMERICAS 35TH FLOOR, NEW YORK NY 10019
Michael Amoroso	officer: Chief Operating Officer	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Vishwas Seshadri	director, officer: Chief Executive Officer	64 STRYKER COURT, BRIDGEWATER NJ 08807
Leila Alland	director	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Christine Berni Silverstein	officer: Chief Financial Officer	C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Joseph Walter Vazzano	officer: Chief Financial Officer	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Brendan M. O'malley	officer: SVP, General Counsel	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Adage Capital Partners, L.p.	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Management, L.p.	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners Gp, L.l.c.	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Edward Carr	officer: Vice President, Controller	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Todd Wider	director	4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219